Paul Schwarzlmueller

Paul Schwarzlmueller

Auto-generated profile, based on publicly available information

Paul Schwarzlmueller

LMU University Hospital, Department of Medicine IV, Ludwig-Maximilians-University , 80336 Munich

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2025 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
PSPaul Schwarzlmueller
Paul Schwarzlmueller
ATAlexandra Triebig
Alexandra Triebig
GAGuillaume Assié
Guillaume Assié
AJAnne Jouinot
Anne Jouinot
STSebastian Theurich
Sebastian Theurich
MKMatthias Kroiss
Matthias Kroiss

25 September 2023 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
PSPaul Schwarzlmueller
Paul Schwarzlmueller
SCStefanie Corradini
Stefanie Corradini
MSMax Seidensticker
Max Seidensticker
PZPetra Zimmermann
Petra Zimmermann
JSJochen Schreiner
Jochen Schreiner
MKMatthias Kroiss
Matthias Kroiss
The response rate of advanced adrenocortical carcinoma (ACC) to standard chemotherapy with mitotane and etoposide/doxorubicin/cisplatin (EDP-M) is unsatisfactory, and benefit is frequently short lived. Immune checkpoint inhibitors (CPI) have been examined in patient’s refractory to EDP-M, but objective response rates are only approximately 15%. High-dose rate brachytherapy (HDR-BT) is a catheter-based internal radiotherapy and expected to favorably combine with immunotherapies. Here we describe three cases of patients with advanced ACC who were treated with HDR-BT and the CPI pembrolizumab. None of the tumors were positive for established response markers to CPI. All patients were female, had progressed on EDP-M and received external beam radiation therapy for metastatic ACC. Pembrolizumab was initiated 7 or 23 months after brachytherapy in two cases and prior to brachytherapy in one case. Best response of lesions treated with brachytherapy was complete (n=2) or partial response (n=1) that was ongoing at last follow up after 23, 45 and 4 months, respectively. Considering all sites of tumor, response was complete and partial remission in the two patients with brachytherapy prior to pembrolizumab. The third patient developed progressive disease with severe Cushing’s syndrome and died due to COVID-19. Immune-related adverse events of colitis (grade 3), gastroduodenitis (grade 3), pneumonitis (grade 2) and thyroiditis (grade 1) occurred in the two patients with systemic response. HDR-BT controlled metastases locally. Sequential combination with CPI therapy may enhance an abscopal antitumoral effect in non-irradiated metastases in ACC. Systematic studies are required to confirm this preliminary experience and to understand underlying mechanisms.

26 June 2025 in European Journal of Endocrinology
Verified
Journal Article
Open access
IWIsabel Weigand
Isabel Weigand
ATAlexandra S Triebig
Alexandra S Triebig
TMTanja Maier
Tanja Maier
TATanja Anderlik
Tanja Anderlik
HRHanna Remde
Hanna Remde
MKMatthias Kroiss
Matthias Kroiss
Purpose: Treatment options for adrenocortical carcinoma (ACC), where mitotane remains a mainstay of therapy, are unsatisfactory. Response rates of ACC to immune checkpoint inhibition (ICI) are disappointing, and immune cells are scarce in ACC. Growth/differentiation factor 15 (GDF-15) is a cytokine impairing tumoural immune infiltration. We here aimed to assess the value of serum GDF-15 for the prognosis of ACC and as a predictor of response to ICI. Methods: GDF-15 was measured in serum samples of 151 patients and correlated with clinical data. Serum GDF-15 was analysed in a second cohort of 46 ACC patients who received ICI, including 14 responders. mRNA expression of GDF15 and genes related to immune response was quantified in 58 ACC tumour samples. Results: We found GDF-15 induction in ACC cells and patients upon mitotane treatment. In ACC patients, serum GDF-15 concentration below the median was associated with significantly longer patient survival. GDF-15 levels in responders to ICI were significantly lower than in non-responders (P = .0379), and patients with low GDF-15 levels had a significant longer progression-free survival than patients with higher GDF-15 serum levels (P = .036). Expression of pro-inflammatory immune-related genes was lower in ACC tissue with GDF-15 expression above the median. Conclusions: Mitotane increases GDF-15 levels and is associated with poor response to ICI. GDF-15 may mediate reduced infiltration with immune cells in ACC.

9 October 2025 in bioRxiv
Verified
Preprint
Open access
MZMagdalena Zaucha
Magdalena Zaucha
EWElena Winheim
Elena Winheim
ASAntonio Santos-Peral
Antonio Santos-Peral
ADApurva Dhavale
Apurva Dhavale
PSPaul Schwarzlmueller
Paul Schwarzlmueller
AKAnne B. Krug
Anne B. Krug
The live-attenuated yellow fever vaccine 17D-204 (YF17D) activates robust innate immune responses followed by rapid induction of adaptive immunity resulting in long-lasting protection. YF17D triggers the production of type I interferons (IFNs) which have a dual role in antigen presenting cells regulating their infection and contributing to their activation. Infection with YF17D was detected in primary human blood monocytes and conventional dendritic cells (DCs) and in monocyte-derived DCs but was highly restricted by type I IFN. Blocking IFNAR signaling in YF17D-infected PBMC from vaccinated donors resulted in increased activation of YF17D-specific CD8 + T cells. Consistently, peak IFN-alpha plasma levels correlated inversely with the CD8 + T cells response in YF17D vaccinees. Loss of function experiments demonstrated a dominant role of retinoic acid inducible gene I (RIG-I)-like receptors (RLRs) and mitochondrial antiviral signaling protein (MAVS) for type I IFN induction and restriction of YF17D. The type I IFN response was mediated by 5’ tri- or diphosphate dsRNA intermediates that are formed during YF17D infection. In vivo proximity labelling (IPL) of RIG-I and next-generation sequencing confirmed interaction of RIG-I with YF17D-dsRNA in infected cells. Thus, YF17D-triggered RLR-signaling restricts viral replication through type I IFN and thus limits the production of viral antigens that can be presented to T cells.